Arcellx Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ACLX Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
21 Mar 24	SellUS$56,440,000	SR One Capital Management, LP	Company	800,000	US$70.55
12 Feb 24	SellUS$2,410,740	Rami Elghandour	Individual	38,065	US$64.46
12 Feb 24	SellUS$640,352	Christopher Heery	Individual	10,111	US$64.46
04 Jan 24	SellUS$1,606,804	Rami Elghandour	Individual	29,073	US$55.27
04 Jan 24	SellUS$470,551	Michelle Gilson	Individual	8,514	US$55.27
04 Jan 24	SellUS$419,926	Christopher Heery	Individual	7,598	US$55.27
14 Dec 23	SellUS$39,304,000	SR One Capital Management, LP	Company	800,000	US$49.13
01 Jun 23	BuyUS$8,928,136	SR One Capital Management, LP	Company	199,824	US$44.68
01 Jun 23	SellUS$1,133,317	SR One Capital Management, LP	Company	25,556	US$44.35
31 May 23	SellUS$115,099	Rami Elghandour	Individual	2,600	US$44.27
31 May 23	SellUS$13,079,306	SR One Capital Management, LP	Company	315,164	US$41.50
11 May 23	SellUS$45,589,317	SR One Capital Management, LP	Company	1,012,833	US$46.15

Insider Trading Volume

Insider Buying: ACLX insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ACLX?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	6,008	0.0113%
Individual Insiders	134,101	0.252%
General Public	467,118	0.877%
Hedge Funds	3,658,624	6.87%
Public Companies	6,720,803	12.6%
VC/PE Firms	8,290,071	15.6%
Institutions	34,013,590	63.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.4%.

Top Shareholders

Top 25 shareholders own 86.6% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
12.6%	Gilead Sciences, Inc.	6,720,803	US$349.5m	0%	no data
8.53%	Perceptive Advisors LLC	4,544,809	US$236.3m	0%	5.53%
7.69%	FMR LLC	4,099,861	US$213.2m	-6.38%	0.01%
7.03%	New Enterprise Associates, Inc.	3,745,262	US$194.8m	0%	10.67%
6.87%	Paradigm Biocapital Advisors LP	3,658,624	US$190.2m	0%	9.67%
5.66%	BlackRock, Inc.	3,018,538	US$157.0m	0%	no data
4.57%	Suvretta Capital Management, LLC	2,435,974	US$126.7m	-15.1%	5.58%
4.4%	SR One Capital Management, LP	2,346,630	US$122.0m	-25.4%	35.48%
4.1%	T. Rowe Price Group, Inc.	2,182,579	US$113.5m	18.2%	0.01%
3.87%	The Vanguard Group, Inc.	2,061,819	US$107.2m	1.14%	no data
3.33%	State Street Global Advisors, Inc.	1,773,839	US$92.2m	-11.9%	no data
3.19%	Cormorant Asset Management, LP	1,700,000	US$88.4m	-20.9%	4.98%
2.89%	Janus Henderson Group plc	1,538,210	US$80.0m	-13.4%	0.04%
2.25%	Lord, Abbett & Co. LLC	1,196,567	US$62.2m	8.97%	0.2%
1.47%	Geode Capital Management, LLC	785,402	US$40.8m	6.27%	no data
1.36%	Deep Track Capital, LP	725,145	US$37.7m	0%	1.32%
1.18%	Morgan Stanley, Investment Banking and Brokerage Investments	631,408	US$32.8m	623%	no data
1.02%	JP Morgan Asset Management	546,156	US$28.4m	14.7%	no data
0.86%	Samsara BioCapital LLC	460,441	US$23.9m	-25%	4.8%
0.68%	Northern Trust Global Investments	363,421	US$18.9m	-1.1%	no data
0.64%	Affinity Asset Advisors, LLC	340,000	US$17.7m	-15%	4.27%
0.63%	PFM Health Sciences, LP	335,198	US$17.4m	39.5%	1.09%
0.62%	Adage Capital Management, L.P.	332,904	US$17.3m	-15.3%	0.03%
0.59%	StemPoint Capital LP	313,604	US$16.3m	0%	4.62%
0.55%	Goldman Sachs Group, Investment Banking and Securities Investments	291,344	US$15.1m	-64.5%	0.01%